Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
NLRP3
Biotech
Ventyx posts Parkinson's data ahead of potential Sanofi talks
The readout shows the effect of VTX3232 on biomarkers, providing data that will influence whether Sanofi takes up its right of first negotiation.
Nick Paul Taylor
Jun 17, 2025 9:05am
NodThera's NLRP3 inhibitor shows obesity promise in early trial
Jun 12, 2024 7:00am
NodThera's NLRP3 inhibitor nearly matches Wegovy for weight loss
Feb 21, 2024 8:30am
Novo enters NLRP3 arena, paying Ventus $70M for NASH hopeful
Sep 29, 2022 9:30am
